PURPOSE:To evaluate the safety and efficacy of multiwavelength photobiomodulation (PBM) in nonexudative (dry) age-related macular degeneration (AMD). METHODS:LIGHTSITE III used a double-masked, randomized, sham-controlled, parallel-group, prospective study design. Subjects were enrolled with a diagnosis of dry AMD and treated with multiwavelength PBM (Valeda Light Delivery System; 590, 660, and 850 nm) or sham treatment. A treatment series included 9 PBM or sham treatments delivered 3x/week over 3 to 5 weeks every 4 months (M) for 24M. RESULTS:A total of 148 eyes (100 subjects) with dry AMD were randomized into the study. LIGHTSITE III met the prespecified primary BCVA efficacy end point at M21 with a significant difference between treatment groups ( P = 0.0036) and a +6.2 letter gain after PBM. At M21, 61.5% of PBM-treated eyes showed ≥5, 23.1% showed ≥10, and 4.4% showed ≥15 letter gains. A favorable safety profile was observed with no signs of phototoxicity. Disease progression to Geographic Atrophy (GA) showed a significant decrease in incidence (Sham, 24.0% vs. PBM, 6.8%; P = 0.007) after PBM treatment at M24. Significant benefit in vision QoL was observed. CONCLUSION:Multiwavelength PBM represents an interventional therapy that restores visual function and has potential disease-modifying effects in intermediate dry AMD.
Vitreoretinal operating rooms face increasing challenges, including workforce shortages and growing patient demand from aging populations. This comparative time-and-motion study assessed if the UNITY® Vitreoretinal Cataract System (UNITY VCS) was associated with differences in console-associated workflow performance in vitreoretinal surgery compared with the CONSTELLATION® Vision System. A prospective, observational, time-and-motion study using a sequential pre–post design was conducted at two sites from May 2024 through July 2025. Adult patients undergoing 25-gauge vitreoretinal surgery were enrolled and received surgery with either the CONSTELLATION or UNITY VCS. The primary endpoint was the duration of console-associated vitreoretinal surgical workflow. Microscope recordings and dedicated operating room (OR) cameras were used to capture surgical steps and timecodes. Data were analyzed using independent t tests with multiplicity adjustment, and mixed-effects models accounting for site and surgeon clustering were used to confirm findings. UNITY VCS was associated with a significantly shorter duration of console-associated vitreoretinal surgical workflow compared with CONSTELLATION (27.3 vs. 32.4 min; absolute mean difference, 5.1 min [95
Abstract Purpose To evaluate the safety and exploratory outcomes of a single intravitreal injection of OGX110, a peptide agonist of CXCR3, in eyes with persistent fluid secondary to neovascular age-related macular degeneration (nAMD) despite ongoing anti-vascular endothelial growth factor (anti-VEGF) therapy. Methods This prospective, open-label, sequential dose-escalation phase I study ( NCT05904691 ) enrolled subjects receiving standard-of-care intravitreal anti-VEGF therapy. Subjects received a single intravitreal injection of OGX110 at 0.5 mg, 1.0 mg, or 2.0 mg (n=3 per cohort), 7 to 14 days after the anti-VEGF injection. Results All nine enrolled subjects completed follow-up through day 56. Two subjects (22%) experienced at least 1 adverse event (AE); all were mild and unrelated to study treatment. Exploratory analyses showed a BCVA change of +1.4 letters following anti-VEGF injection and +4.4 letters from OGX110 baseline to 4 weeks (P < 0.05). Six of 9 subjects gained at least 3 ETDRS letters after OGX110. Anatomic responses were heterogeneous. Four eyes showed a reduction in CRT after anti-VEGF injection that was maintained after OGX110 administration. One additional eye demonstrated a substantial reduction in CRT after OGX110 despite minimal response to anti-VEGF treatment. Conclusions A single intravitreal injection of OGX110 was well tolerated. Exploratory functional and anatomic findings suggest biologic activity; interpretation is limited by small sample size, open-label design, absence of a concurrent control group, and inter-subject heterogeneity. These results support further study in a controlled trial. Translational Relevance OGX110 represents a mechanistically distinct investigational approach for nAMD that may warrant further evaluation in eyes with persistent.
Abstract Purpose Timely detection of disease activity in chronic retinal diseases improves visual outcomes but is limited by the lack of validated systems for continuous monitoring and care management. We evaluated the real-world performance of an integrated remote physiologic monitoring and principal care management program (RemoniHealth®) using a self-administered multimodal retinal function test (Macustat®) for home monitoring. Methods This single-arm real-world intervention study was conducted across 33 retina practices. A total of 2,216 adults with chronic retinal diseases performed weekly home retinal function testing with integrated care management support. Primary endpoints included the annualized rate of disease progression detection, time to intervention after first flag, true positive rate, and patient adherence. Descriptive statistics and data analyses were analyzed using chi-square tests and Clopper–Pearson confidence intervals. Results Participants contributed 82,644 encounters and 16,805 patient-months of monitoring. The program generated 241 alerts, including 101 Macustat flags and 135 care management prompts. Among 73 adjudicated flags, 56 were true positives and 17 false positives (PPV 76.7%). The annualized detection rate was 4 per 100 patient-years. Of confirmed events, 93% led to intravitreal injection or other major management change. Mean adherence was 72.1%, and patients with ≥80% adherence had higher odds of true positivity. Discussion This RPM–PCM model achieved high engagement and meaningful detection of asymptomatic progression between visits, supporting the value of home monitoring for timely intervention. Translational Relevance These findings support scalable integration of home vision testing and care management into routine retinal practice to enable earlier intervention and improved continuity of care.
Purpose:To report efficacy of intravitreal pegcetacoplan treatment over 36 months in eyes with subfoveal geographic atrophy (GA). Patients and Methods:The GALE (NCT04770545) open-label extension trial adds 12 months of results to the 24-month Phase 3 OAKS (NCT03525613) and DERBY (NCT03525600) trials, representing up to 36 months of continuous pegcetacoplan treatment. They included a heterogeneous population of eyes with subfoveal GA (63%). Pegcetacoplan-treated eyes enrolling in GALE continued at the same interval of pegcetacoplan monthly (PM) or every other month (PEOM). Patients' eyes in sham monthly or every-other-month arms crossed over to receive pegcetacoplan in GALE at the same interval (sham crossover). Consequently, projected sham, calculated from prior 24-month GA growth rate of sham-observed eyes in OAKS and DERBY averaged across four 6-month segments, was the comparator for the first 12 months of GALE (months 24-36). This analysis reports results of eyes with subfoveal GA at baseline. Results:In eyes with subfoveal GA, 84% had best corrected visual acuity (BCVA) ≥20/200 and 38% had BCVA ≥20/63 at OAKS and DERBY baseline. Pegcetacoplan reduced subfoveal GA growth rate by 21% (p<0.0001) with PM and 19% (p=0.0001) with PEOM over 36 months. Increasing efficacy over time was noted between months 24 and 36; 31% reduction in subfoveal GA growth rate with PM and 25% reduction with PEOM (both p<0.0001) compared with projected sham. Microperimetry demonstrated significant reduction in formation of absolute scotomas with PM at 24 months (-2.5 number of scotomas formed; 95% confidence interval [CI]: -4.5, -0.4; p=0.0205) and 36 months (-4.0 number of scotomas formed; 95% CI: -6.8, -1.2; p=0.0050), compared to sham crossover in subfoveal GA. Safety profile in GALE was consistent with OAKS and DERBY. Conclusion:Long-term efficacy of pegcetacoplan in slowing GA progression was demonstrated over 36 months in eyes with subfoveal GA.